Member Info for The_Paladin

I am hoping for a return to a higher share price in the near future. The current MCap makes no sense whatsoever. The recent information concerning IB’s high definition tumour imaging underpinned by AI driven diagnostics, and the progress made in the GaM trial, suggests that the company is undervalued.

Unfortunately, this is contradicted by the recent placement, which literally halved the share price from an already low level of 1.4p. The CEO and Board would not be raising funds, presumably to pay their salaries and other company expenses, if there was imminent news to the company’s advantage on the horizon?

Currently, the sell price for 50K shares is 0.751p. Is this the bottom? Were they recent sells partly to do with the fact that we are nearing the end of the financial year? Were recent purchasers of IQAI stock disposing of it due to lack of progress? Perhaps the issuing of 25m new shares for a tiny amount prompted the sells?

I can but speculate because I don’t know. Like others here, I can but hope that the investments of long term retail investors are part of this company’s future plans. Having seen the shabby treatment recently dispensed on LTIs by another tiny company recently, I remain wary! GLA.

“revenue” not “revenge”.

Today’s first trade suggests that the share dumping is continuing and that a lower share price beckons?

An excellent summary howdlep, as always. I am aware from your previous posts that your research is detailed and thorough.

I agree that TB’s activities are currently determining the course of this company. It would appear that he is focused on benefiting himself, and his associates, apparently to the detriment of retail investors? It is probably time for him to step down.

MS would be an ideal replacement, as the future of the company rests on what IB is able to achieve. I have little information about IB’s revenue and projected future growth. Currently it rests on the sales of its diagnostic products; hopefully they are going down a licensing route, to generate continued revenge for future upgrades to their software?

I appreciate that the GaM trial is another iron in the fire. As is the case with clinical trials, it is taking a long time to complete the Ph1 stage. It seems likely that it will subsequently progress to a Ph2 trial. Hopefully, TB will not be involved at the Ph2 funding stage. Past precedent suggests that he might work it to his own advantage, with a massive share dilution to the detriment of current retail investors?

Unfortunately, I recently lost a lot of capital in a biopharmaceutical company, which was totally mismanaged by an incompetent CEO, and inexperienced CSO. The executives of IQAI are nowhere near that category, but I am more wary than before. As an investor, it is my view that it is high time that we were given some evidence of progress in IB’s promising initiatives. As said previously, the newsletters and X messages are indicative of progress, but add no value. Hopefully, some indication of future revenue growth will be forthcoming? GLA

Unfortunately, the company’s overall lack of activity during the last 18 months has resulted in a hugely depleted share price, and a negative sentiment.

advfn are now producing AI produced summaries of contributors comments on their investor chat forums. Here is the recent one for IQ-AI:

“Recent investor discussions regarding IQAI (Iq-ai Limited) have highlighted a concerning sentiment among shareholders. Notable comments, such as "Yep, this one is dead in the water," emphasize a growing pessimism regarding the stock's performance. Investors appear to be bracing for declines, with one user expressing a "sinking feeling" as the stock approaches a low of 0.0075. There is also speculation about increased selling activity leading up to the end of the tax year, which could add to the downward pressure on the stock price.

Overall, the financial highlights from these discussions indicate a lack of confidence in the company’s future prospects, with many investors voicing doubts about the stock's ability to recover. Critical insights reveal an overarching fear of further depredation in stock value, aligning with recent trends and overall investor sentiment that leans towards cautious pessimism. Such discussions serve as a reflection of the broader challenges faced by IQAI in the market landscape.”

The selling continues, at new 52-week low share prices. If what we are being told by IB is correct, there is no logical explanation for this?

Is last week’s placement going to result in halving the share price ( to 0.7p) from last Monday’s 52-week low?

It is high time for the company to get a grip! Positive newsletters, and regular X posts with high definition state of the art images of tumours are having no impact at present! We are more like a very early stage University spinoff, than a company en route to growth and profitable activity?

Some fair points were made by semantic regarding the recent placement. I am convinced though that such a small sum will only serve to cover the company’s basic running costs for another year. The claims made regarding the allocation of these funds doesn’t tally with me. There simply isn’t enough capital to disseminate significant sums between our areas needing development.

On a more positive note, having re-read the information concerning the company’s innovative products, and the GaM trial, I strongly agree with others that IQ-AI/IB is significantly undervalued by the market at present.

One further point. Whatever happened to Stone Checker? Little has been documented about it in recent years?

https://healthairegister.com/products/imaging-biometrics-stonechecker/

Will it be further enhanced? Does it have a future as a part of the company’s repertoire of advanced diagnostic technologies ?

Evidently, more shenanigans as a consequence of the way that IQ-AI is run? Although not an AIM company, IQ-AI is apparently being run for the benefit of the CEO and his associates? It is a disgrace that they are continuously allowed to get away with this!

The share price is currently at around 40% of its value at the start of the year. Its value at the start of the year was around 40% of the peak value going into 2024. A case of ever decreasing circles!

A poor AIM company in all but designation. Despite all the positive news issued earlier this year, the share price decline has been disastrous for long term retail investors.

I find it difficult to reconcile our potential both from the imaging perspective, and from the anticipated GaM trial update with IQ-AI’s current MCap? Surely our IP involving advanced imaging technology linked to AI diagnostics has inherent value? This is not reflected in the share price.

Further, the fragility of the share price following the placement RNS has led to a 50% share price collapse and the third 52-week low in less than a week yesterday.

As an investor, I find this concerning. There was nothing in the company’s statements earlier this year that suggested yet further significant decline following last year’s shenanigans.

I hope that the CEO and Board will address this situation soon, and provide the market with detailed statements predicting further growth in our revenue that are now needed. It seems to me that I may have totally misjudged this company’s potenti? Hopefully not?

The share price has crashed from an already low price of 1.9p on Jan 25 to 0.95 - 0.96p this morning. A 50% decline in less than two months following three optimistic RNS statements this year? Two 52-week low prices were achieved on successive days this week following the RNS. There is nothing to contradict the possibility that the share price may continue to fall today?

The cash raise barely covers the salaries of “executives” and directors’ expenses if that? The CEO needs to address investors, and inform us in detail what is actually going on inside this company. The vague rationale given in Peterhouse Capital’s statement makes little sense.

“The proceeds will be used for clinical trials of GaM (adult and pediatric) and the Expanded Access Program. Additionally, the funds will support and accelerate organic growth, including the completion of the release of IB Clinic and IB Nimble, as well as the expansion of the marketing and sales teams.”

Are we supposed to believe that the latter could be achieved from £250K minus the usual deductions?

Howdlep.

I was still writing my last post when your reply was posted. Thank you for the additional clarification which has moved me forward in my understanding of what might be happening?

ATB.

Howdlep,

Many thanks for your clear explanation. It is much appreciated.

Should the company eventually be sold on at a higher share price than today’s low value, BRH will still achieve a greater return as a result of their increased shareholding. This is what confused me earlier.

There is still hope for investors here, although I was previously thinking in terms of a partnership deal with a large entity, or something similar? That seemed a reasonable way forward given the company’s RNSs and optimism earlier this year?

I cannot see how raising a tiny amount of capital, at significant dilution, can be of much value to IQ-AI/IB or its investors? We shall have to remain patient and see what develops?

Thanks again, and ATB.

Ditto max 500,000 dummy sell @ 0.985p per share.

Oddly, when I went through a similar “dummy selling”process earlier today, even a tiny sell of 1000 shares could be achieved by a negotiated trade.

As predicted, the 52-week low has been reached , with perhaps a new low to follow? A confirmation that this company’s Board do not represent the best interests of retail investors.

Today’s actions are not commensurate with the apparent optimism concerning IB’s technology given in earlier RNS statements this year?

Nearly 1m shares sold today, to date. Most were sold at a price close to the Placement price. This may serve to drive the share price back to a 12 month low?

Once again, the activity of this company does not appear to be in the best interest of retail investors? Why weren’t we presented with an opportunity to participate in the Placement?

Even the eloquent “semantic” would have difficulty in explaining that today’s developments are in the best interest of all investors?

I agree Tyke. We are under informed with regard to any financial detail concerning our investment. Additionally, I don’t understand how the reduction in Braveheart’s % involvement in IQ-AI came about, when one looks at their RNS statement earlier today?

Unfortunately given my recent experience, this placement does not bode well with me. ATB.

“Braveheart Investment Group plc (AIM: BRH) announces the participation in IQ-AI Ltd's ("IQ-AI") placing to raise £250,000 (the "Placing") via the issuance of 25,000,000 new ordinary shares (the "Placing Shares") at a price of £0.01 per share (the "Issue Price"). The Company, an existing shareholder in IQ-AI, has subscribed for 7,000,000 Placing Shares for a consideration of £70,000. On admission of the Placing Shares, the Company will hold 72,415,862 ordinary shares in IQ-AI which represents 29.35% of the issued share capital of IQ-AI as enlarged by the Placing.”

Unfortunately that seems to be the case max. For sure, retail investors were not invited to participate.

The comment “The Placing was undertaken with existing and new shareholders” is particularly galling. This is very annoying for me, as I have recently experienced something similar (far worse if anything, as retail investors were led up a placement garden path only to be jettisoned ) with a failed AIM biopharmaceutical company.

With the tiny sum raised through a significant placing, this can only lead to further dilution of our shares IMO.

Another disappointing initiative from IQ-AI.

An additional 25m shares has resulted in a significant dilution to the share price. Moreover, the £250K raised is hardly significant in funding a trial and access programme? I am highly cynical as to why this placing was carried out?

With apologies. My mental arithmetic has failed me this morning.

$425m ( AZ’s initial payment) x 0.77 £/$ = £327.25m

Divide this by 221.71m (the number of IQ-AI shares in circulation) gives around 148p per share. Perhaps my target of 30p per share as an IQ-AI takeover target is a reasonable guesstimate? Hopefully, we shall receive more detailed information from the company this year?GLA

Thank you Tyke. It is appropriate to retain a measure of optimism, with some justification, as far as IB is concerned.

It was interesting to that AZ’s interest is centred on an innovative delivery method. Further, they will pay a chunky initial payment by the end of H1, with the residue, up to $1B in total, in subsequent milestone payments. One half of the initial payment, as a takeover bid, would result in an IQ-AI share price of 90 - 100p.

My aspiration is well below this price range, this being around 30p per share? My “valuation” is mostly guesswork. The three RNS statements to date this year, offer us optimism with insufficient detail to make any predictions as to the company’s intrinsic value?

I intend to keep my shares on hold and will probably buy a few more in the next financial year. My plan is to pursue this to a conclusion whatever may happen in the future? GLA.